Published October 19, 2011
BOSTON – A Massachusetts and 12 other groups working to stop the HIV/AIDS epidemic are pressing federal officials to quickly review the use of a daily pill to prevent new infections in gay and bisexual men and transgender women.
The AIDS Action Committee of Massachusetts and other groups say the U.S. Food and Drug Administration and drug maker Gilead Sciences Inc. should not to delay review of the use of a daily HIV medication to reduce the risk of infection for gay and transgender people because of doubts about its efficiency in heterosexual populations.
The U.S. Centers for Disease Control estimates that gay men and transgender women account for more than half of all new HIV infections in the country.
California-based Gilead Sciences makes Truvada for treating HIV.